WA-KYMETA
2.12.2020 10:36:09 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com )—the communications company making mobile global—announced that the Kymeta™ u8 and Kymeta Connect™ are available for government and commercial purchase after November 30, 2020, unlocking the potential of broadband satellite connectivity and cellular networks to satisfy the overwhelming demand for communications on the move.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005022/en/
Kymeta’s next-generation solutions are built for mobility and designed to meet the needs of global defense agencies, government, first responders, and commercial customers. Kymeta’s products and services have been field deployed for three years and the demand for the Kymeta u8 presales has already exceeded expectations. With the introduction of the Kymeta u8, the company has meaningfully increased antenna throughput and significantly reduced the total cost of ownership. Kymeta’s new products and services offer a breakthrough in performance, ease of use, and affordability, and it anticipates that these solutions will further enhance its position in both commercial and government markets, further increasing its lead over competitive offerings.
“Government and military need the most reliable and seamless connectivity to safely fulfill their missions,” said Walter Berger, Kymeta President, and COO. “These men and women often go to the most remote or disaster-stricken areas of the world, and they need reliable communications to rescue lives, keep property safe, and complete missions. Our government, military, and commercial customers trust Kymeta solutions. The enhanced performance of the u8 is helping our customers make fast, easy, and reliable mission-critical communications on the move a reality.”
The launch of Kymeta’s next-generation solutions builds on the successful deployment of our beta program earlier this year to facilitate real-world testing. The testing demonstrated throughputs of over 45Mbps in land mobile environment with large scan-off angles of over 50 degrees, which is a remarkable achievement for such a low power (<150W) electronically steered antenna platform. The u8 was tested in regions around the world including North America, APAC, and Europe, in a variety of conditions confirming that the product can be operated with confidence even under the most trying scenarios.
“My team works in some of the most densely populated, rugged, and steep forest terrain in the U.S.,” said Tim Dunfee, Deputy Forest Fire Chief, U.S. Forest Service. “There are places across our varied terrain that have been engulfed by fires and communications cell towers that have been destroyed, causing loss of all communications. When we tested Kymeta’s solutions, we could use FaceTime and make voice calls for the first time. We now have a Kymeta antenna installed on one of our vehicles and deploy it to every forest fire because we know it has reliable communications wherever it goes.”
The Kymeta u8 covers the full Ku-band and is designed to be LEO upgradeable. The u8 is available as an antenna, an ODU (with no modem), and a turnkey terminal with embedded satellite modem, cellular modem, and SD-WAN capabilities. The Kymeta terminals are easy to set up and they acquire service within minutes of being powered. Also coming soon is a transportable configuration called the u8 GO, which is ideal for rapid deployments. The u8 GO will enable safe transport with a hardened case for protection and provides a built-in car mount to support easy operations on the pause and on the move.
Combining the u8 with Kymeta’s hybrid satellite-cellular connectivity services, Kymeta Connect transforms the purchase and consumption of mobile data delivering a complete end-to-end solution with a best-in-industry customer experience. The all-inclusive hybrid satellite-cellular connectivity, global support, and network services package start at $999 per month.
Kymeta Connect is powered by a virtual architecture consisting of an operational stack that connects remote terminals to managed satellite and cellular services, integrates a state-of-the-art digital back office for service and subscription management, and includes an operations and care element to deliver an excellent customer experience. These services are augmented with a unique application called Access which simplifies the control, management, and monitoring of all hardware and connectivity solutions. The newly announced app is available for download through the Apple and Google Play stores. Today, Kymeta Access can be used on a tablet or through a web-based portal to interact with hardware, data, customer care, and subscription services.
Kymeta expects to further accelerate its new product development and commercialization of its next-generation solutions and looks forward to sharing more in 2021.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best in class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005022/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom